Treatment of Proliferative Diabetic Retinopathy with Panretinal Photo Coagulation and Anti VEGF Injection, Depending on the Case

Ermal Simaku, Etleva Gjurashaj

Abstract


Proliferative diabetic retinopathy (PDR) is the most common cause of severe visual loss in people with diabetes. Although panretinal photocoagulation (PRP) remains one of the best treatment, it has many side effects. So other new treatment modalities have emerged. These  can be used to increase the extent of treatment, expedite the effect of laser treatment and provide alternate measures when laser delivery is difficult or impossible, especially in patients with vitreous haemorrhage, or when the patient is at young age.  Currently, most of the research in this field is focussed on inhibitors of vascular endothelial growth factor (VEGF). Although limited by their short-lived effects, anti-VEGF agents are widely available, especially for the treatment of aggressive PDR. We present 2 cases which  had regression of neovascularization within  four weeks of the initial treatments, and  maintained their visual acuity with no evidence of recurrent neovascularization through 12 months after initiating treatment. Intravitreous injections of anti-VEGF therapy may be an alternative treatment option for patients with PDR. We followed  a system of 3 injection q4wk followed by injection q8wk,  depending on gravity of macular edema and it’s regression from anti-VEGF intravitreal injections.  

Keywords:  PRP, PDR, VEGF, DME, etc.  


Full Text:

PDF

References


Retina in systemic disease : a color manual of ophthalmoscopy / Homayoun Tabandeh, Morton F. Goldberg 2009.

Treatment of proliferative diabetic retinopathy with anti-VEGF agents | Request PDF. Available from: https://www.researchgate.net/publication/49811184_Treatment_of_proliferative_diabetic_retinopathy_with_anti-VEGF_agents [accessed Mar 19 2018].

Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetesin the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: 2011.

Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 Suppl):823-33.

Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Archives of ophthalmology. 2004;122(4): 552-63.

Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005; 353(8): 839-41.

Early Treatment Diabetic Retinopathy Study Research Group. Early Photocoagulation for Diabetic Retinopathy. ETDRS report number 9. Ophthalmology. 1991; 98(5): 766-85.

Jardeleza MSR, Miller JW. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Seminars in ophthalmology. 2009; 24(2): 87-92.




DOI: http://dx.doi.org/10.0001/ijllis.v7i4.1674

DOI (PDF): http://dx.doi.org/10.0001/ijllis.v7i4.1674.g2145

Copyright © 2012-2020 ANGLISTICUM. Journal of the Association-Institute for English Language and American Studies,Tetovo, Republic of North Macedonia.

All Rights Reserved.

The publication is licensed under a Creative Commons License (CC BY) https://creativecommons.org/licenses/by/4.0/  View Legal Code                                                                                                                 

ISSN (print): 1857-8179. ISSN (online): 1857-8187.

Disclaimer: Articles on Anglisticum have been reviewed and authenticated by the Authors before sending for the publication.

The Journal, Editors and the editorial board are not entitled or liable to either justify or responsible for inaccurate and misleading data if any. It is the sole responsibility of the Author concerned.